These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 2174966

  • 21. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, Pollack IF, Bozik ME, Chambers WH.
    Cancer Res; 2000 May 01; 60(9):2449-57. PubMed ID: 10811123
    [Abstract] [Full Text] [Related]

  • 22. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M.
    J Immunol; 1999 Mar 15; 162(6):3574-82. PubMed ID: 10092816
    [Abstract] [Full Text] [Related]

  • 23. T lymphocytes infiltrating sites of tumor rejection and progression display identical V beta usage but different cytotoxic activities.
    Kurt RA, Park JA, Panelli MC, Schluter SF, Marchalonis JJ, Carolus B, Akporiaye ET.
    J Immunol; 1995 Apr 15; 154(8):3969-74. PubMed ID: 7706735
    [Abstract] [Full Text] [Related]

  • 24. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment.
    Schendel DJ, Gansbacher B.
    Cancer Res; 1993 Sep 01; 53(17):4020-5. PubMed ID: 8358731
    [Abstract] [Full Text] [Related]

  • 25. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
    Wang YL, Si LS, Kanbour A, Herberman RB, Whiteside TL.
    Cancer Res; 1989 Nov 01; 49(21):5979-85. PubMed ID: 2507139
    [Abstract] [Full Text] [Related]

  • 26. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state.
    Yamamoto N, Zou JP, Li XF, Takenaka H, Noda S, Fujii T, Ono S, Kobayashi Y, Mukaida N, Matsushima K.
    J Immunol; 1995 Mar 01; 154(5):2281-90. PubMed ID: 7868900
    [Abstract] [Full Text] [Related]

  • 27. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
    Hillman GG, Younes E, Visscher D, Hamzavi F, Kim S, Lam JS, Montecillo EJ, Ali E, Pontes JE, Puri RK, Haas GP.
    Clin Cancer Res; 1997 Oct 01; 3(10):1799-806. PubMed ID: 9815566
    [Abstract] [Full Text] [Related]

  • 28. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.
    Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ.
    J Immunol; 1994 Aug 15; 153(4):1697-706. PubMed ID: 7913943
    [Abstract] [Full Text] [Related]

  • 29. Generation of MC-38 adenocarcinoma tumor-specific tumor infiltrating lymphocytes by murine anti-CD3 antibody and recombinant interleukin-2.
    Lafreniere R, Borkenhagen K, Bryant LD.
    Mol Biother; 1991 Mar 15; 3(1):26-33. PubMed ID: 1829898
    [Abstract] [Full Text] [Related]

  • 30. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
    Ogasawara M, Rosenberg SA.
    Cancer Res; 1993 Aug 01; 53(15):3561-8. PubMed ID: 8101762
    [Abstract] [Full Text] [Related]

  • 31. Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status.
    Ritter M, Huber C, Auböck J, Pohl-Markl H, Troppmair J, Herold M, Gächter A, Nussbaumer W, Böck G, Nachbaur D.
    Immunology; 1994 Apr 01; 81(4):569-77. PubMed ID: 7913694
    [Abstract] [Full Text] [Related]

  • 32. Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes.
    Stötter H, Wiebke EA, Tomita S, Belldegrun A, Topalian S, Rosenberg SA, Lotze MT.
    J Immunol; 1989 Mar 01; 142(5):1767-73. PubMed ID: 2493053
    [Abstract] [Full Text] [Related]

  • 33. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma.
    Sheu BC, Chiou SH, Lin HH, Chow SN, Huang SC, Ho HN, Hsu SM.
    Cancer Res; 2005 Apr 01; 65(7):2921-9. PubMed ID: 15805295
    [Abstract] [Full Text] [Related]

  • 34. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT, Palladino MA, Jaffe HS, Espevik TP, Rayner AA.
    Cancer Res; 1988 Oct 15; 48(20):5864-7. PubMed ID: 3139285
    [Abstract] [Full Text] [Related]

  • 35. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity.
    Chou T, Chang AE, Shu SY.
    J Immunol; 1988 Apr 01; 140(7):2453-61. PubMed ID: 2450925
    [Abstract] [Full Text] [Related]

  • 36. Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity.
    Yang X, Chu Y, Wang Y, Zhang R, Xiong S.
    J Leukoc Biol; 2006 Dec 01; 80(6):1434-44. PubMed ID: 16980511
    [Abstract] [Full Text] [Related]

  • 37. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y, Saxena A, Zheng C, Carlsen S, Xiang J.
    J Gene Med; 2004 Aug 01; 6(8):857-68. PubMed ID: 15293344
    [Abstract] [Full Text] [Related]

  • 38. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
    Musiani P, Allione A, Modica A, Lollini PL, Giovarelli M, Cavallo F, Belardelli F, Forni G, Modesti A.
    Lab Invest; 1996 Jan 01; 74(1):146-57. PubMed ID: 8569177
    [Abstract] [Full Text] [Related]

  • 39. An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity.
    Yang JC, Perry-Lalley D, Rosenberg SA.
    J Biol Response Mod; 1990 Apr 01; 9(2):149-59. PubMed ID: 1971302
    [Abstract] [Full Text] [Related]

  • 40. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct 01; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.